Sapphiros
Sapphiros is a private equity growth and expansion firm founded in 2021 and based in Massachusetts. The company specializes in investing in growth-stage diagnostic companies, emphasizing innovative and patient-centric technologies. Its portfolio includes a diverse range of capabilities, such as advanced sample collection methods, next-generation diagnostics, computational biology, and printed electronics. By focusing on these areas, Sapphiros aims to enhance the global accessibility of essential diagnostic results for consumers, thereby contributing to advancements in healthcare and diagnostic-related innovations.
2 past transactions
Flexotronix
Acquisition in 2022
Flexotronix is a privately held Innovation and manufacturing company focused on developing high-volume manufacturing technologies and flexo-printed electronics
BioCrucible
Acquisition in 2021
BioCrucible is focused on advancing biotechnology through the development of next-generation diagnostics that leverage innovative biomolecular condensate formation. The company is dedicated to creating a highly sensitive and specific molecular diagnostic product aimed at improving healthcare in underdeveloped countries, particularly for testing and treating infectious diseases. Utilizing a proprietary technology platform, BioCrucible enhances and accelerates the kinetics and behavior of engineered biological systems, positioning itself to address critical health challenges in global populations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.